Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary infiltrate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Pulmonary infiltrate. Displaying page 2 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2015-001868-19 Sponsor Protocol Number: 2015-001 Start Date*: 2015-10-15
    Sponsor Name:University medical center of Johannes Gutenberg University Mainz
    Full Title: A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study
    Medical condition: severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002165-34 Sponsor Protocol Number: RC19_0292 Start Date*: 2020-12-03
    Sponsor Name:CHU of Nantes
    Full Title: Predictive Signature of Benralizumab Response
    Medical condition: Severe asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000105-65 Sponsor Protocol Number: 1 Start Date*: 2006-08-30
    Sponsor Name:Medical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases
    Full Title: Comparative study of the efficacy and tolerance of intravenously administered azithromycin (1.5 g) given either as a single dose or over a 3 day period in patients with community-acquired pneumonia
    Medical condition: community aquired pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023342-67 Sponsor Protocol Number: C38072/3081 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) wit...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002110-35 Sponsor Protocol Number: CL06-001 Start Date*: 2006-08-24
    Sponsor Name:Advanced Life Sciences
    Full Title: A Double-Blinded, Randomized, Parallel group, Multi-Centre, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300mg QD to Clarithromycin (KLACID®) 250mg BID for the treatme...
    Medical condition: Community Acquired Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) EE (Completed) DE (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001406-17 Sponsor Protocol Number: 48009 Start Date*: 2015-01-21
    Sponsor Name:Erasmus MC
    Full Title: Ventilator Associated Pneumonia: addition of Tobramycin Inhalation antibiotic treatment to standard IV antibiotic treatment
    Medical condition: ICU patients with ventilator-associated pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001730-17 Sponsor Protocol Number: BAP00248/307 Start Date*: 2004-09-16
    Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Full Title: A Phase 3, Randomized Double-Blind Study of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia
    Medical condition: Nosocomial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) HU (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-000404-15 Sponsor Protocol Number: 34666 Start Date*: 2019-04-29
    Sponsor Name:Thomas Benfield
    Full Title: Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial
    Medical condition: Community-acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    22.1 10021881 - Infections and infestations 10035725 Pneumonia NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002867-13 Sponsor Protocol Number: POP6135,HMR3647B/3005 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Multinational, randomized, double blind, double dummy, pharmacokinetic study of telithromycin oral suspension (25 mg/kg once daily for 7-10 days), with secondary assessments of safety relative to a...
    Medical condition: Community acquired pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-024614-66 Sponsor Protocol Number: C38072/3082 Start Date*: 2011-07-20
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2010-024006-35 Sponsor Protocol Number: C38072/3083 Start Date*: 2011-05-05
    Sponsor Name:Teva Branded Pharmaceutical Products, R&D, Inc.
    Full Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75...
    Medical condition: Treatment for patients with eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-002619-10 Sponsor Protocol Number: OP-634-001 Start Date*: 2004-11-10
    Sponsor Name:Oscient Pharmaceuticals
    Full Title: A Phase IIIb, Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin 320 mg Once Daily for 5 Days Versus Oral Gemifloxacin 320 mg Once Da...
    Medical condition: Mild to moderate community acquired bacterial pneumonia.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010120 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000442-12 Sponsor Protocol Number: KB-101-002 Start Date*: 2008-02-07
    Sponsor Name:Kenta Biotech Ltd
    Full Title: A non-comparative open pilot trial to assess the safety and pharmacokinetics of up to three single doses of AERUMAB 11 in patients with ventilator associated pneumonia caused by serotype O11 P. aer...
    Medical condition: ventilator associated pneumonia (VAP) caused by serotype O11 Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065153 Ventilator associated pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002591-40 Sponsor Protocol Number: P180501J Start Date*: 2018-11-26
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Evaluation of bronchial remodeling during mepolizumab treatment in severe eosinophilic asthma
    Medical condition: severe oesinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003483-46 Sponsor Protocol Number: 10-0060+EU-Appendix5.0,11.12.2014 Start Date*: 2013-11-12
    Sponsor Name:University of Florida Board of Trustees
    Full Title: Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance during the Treatment of Hospitalized Subjects with Pneumonia Requiring Mechanica...
    Medical condition: pneumonia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10060946 Pneumonia bacterial PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004174-24 Sponsor Protocol Number: BAP00248 Start Date*: 2006-08-24
    Sponsor Name:Johnson&Johnson Pharmaceutical Research&Development, L.L.C.
    Full Title: A Phase 3 Randomized, Double-Blind Study of Ceftobiprole Medocaril versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia
    Medical condition: Hospital-Acquired or Nosocomial Pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-000412-33 Sponsor Protocol Number: 3074K6-2000-WW Start Date*: 2008-09-17
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF TIGECYCLINE VERSUS IMIPENEM/CILASTATIN FOR THE TREATMENT OF SUBJECTS WITH HOSPITAL-ACQUI...
    Medical condition: Hospital-Acquired Pneumonia (HAP) including Ventilator-Associated Pneumonia (VAP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035664 Pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) LV (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004385-17 Sponsor Protocol Number: MEA115921 Start Date*: 2013-11-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving St...
    Medical condition: Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004867 10018701 Granulomatous disease LLT
    17.1 100000004864 10014956 Eosinophilic granuloma LLT
    17.1 100000004866 10072580 Granulomatous polyangiitis LLT
    17.1 100000004870 10014957 Eosinophilic granulomatous vasculitis LLT
    17.1 100000004866 10056218 Necrotising granulomatous vasculitis LLT
    17.1 100000004855 10068462 Eosinophilic asthma LLT
    17.1 100000004866 10036023 Polyangiitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003109-28 Sponsor Protocol Number: ICLA-20-PNE1 Start Date*: 2007-09-28
    Sponsor Name:Arpida AG
    Full Title: Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-as...
    Medical condition: Hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035664 Pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003971-20 Sponsor Protocol Number: CE01-300 Start Date*: 2013-05-07
    Sponsor Name:Cempra Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Ac...
    Medical condition: Community-Acquired Bacterial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) PL (Completed) LV (Completed) EE (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 05:40:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA